Suppr超能文献

给予高密度脂蛋白可减轻肝硬化大鼠肝脏的促炎反应,恢复肝脏内皮型一氧化氮合酶活性,并降低门静脉压力。

High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats.

作者信息

Thabut Dominique, Tazi Khalid A, Bonnefont-Rousselot Dominique, Aller Maria, Farges Olivier, Guimont Marie-Christine, Tellier Zera, Guichard Cecile, Ogier-Denis Eric, Poynard Thierry, Moreau Richard, Lebrec Didier

机构信息

INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Paris 75018, France.

出版信息

Hepatology. 2007 Dec;46(6):1893-906. doi: 10.1002/hep.21875.

Abstract

UNLABELLED

In patients with cirrhosis, endotoxic shock is a major complication of portal hypertension, which is related partly to intrahepatic endothelial nitric oxide synthase (eNOS) down-regulation. High-density lipoproteins (HDLs), whose plasma levels are reduced in cirrhosis, have an anti-inflammatory effect by neutralizing circulating lipopolysaccharide (LPS), and they increase eNOS activity in endothelial cells. Therefore, the aim of this study was to assess the effects of reconstituted high-density lipoprotein (rHDL) administration on the LPS-induced proinflammatory response, intrahepatic eNOS regulation, and portal hypertension in cirrhotic rats. Cirrhotic and control rats were pretreated with rHDL or saline and challenged with LPS or saline. The neutralization of LPS in HDL was assessed by the measurement of HDL-bound fluorescent LPS levels. Plasma tumor necrosis factor alpha (TNFalpha) and lipopolysaccharide binding protein (LBP) levels were measured. The expression of hepatic TNFalpha, LBP, inducible nitric oxide synthase (iNOS), and caveolin-1 (a major eNOS inhibitor) and the activity of protein kinase B (Akt; a major eNOS activator) and eNOS were determined. The portal pressure was measured. The plasma HDL levels were significantly lower in cirrhotic rats than in control rats. In cirrhotic rats, the plasma levels of HDL-bound fluorescent LPS were 50% lower than those in controls, and they were restored after rHDL administration. The plasma TNFalpha levels were significantly higher in LPS-challenged cirrhotic rats than in controls and significantly decreased after rHDL administration. rHDL administration decreased hepatic TNFalpha, LBP, iNOS, and caveolin-1 expression, restored hepatic eNOS and Akt activity, and significantly lowered the portal pressure and intrahepatic vascular resistance.

CONCLUSION

In cirrhotic rats, rHDL administration decreases the hepatic proinflammatory signals induced by LPS, restores the hepatic eNOS activity, and lowers the portal pressure. This suggests that the decrease in circulating HDL in cirrhosis plays a role in the excessive proinflammatory response and intrahepatic eNOS down-regulation.

摘要

未标记

在肝硬化患者中,内毒素休克是门静脉高压的主要并发症,这部分与肝内内皮型一氧化氮合酶(eNOS)下调有关。高密度脂蛋白(HDL)在肝硬化患者中的血浆水平降低,它通过中和循环中的脂多糖(LPS)发挥抗炎作用,并增加内皮细胞中的eNOS活性。因此,本研究的目的是评估重组高密度脂蛋白(rHDL)给药对肝硬化大鼠LPS诱导的促炎反应、肝内eNOS调节和门静脉高压的影响。将肝硬化大鼠和对照大鼠用rHDL或生理盐水预处理,然后用LPS或生理盐水进行攻击。通过测量HDL结合的荧光LPS水平评估HDL中LPS的中和情况。测量血浆肿瘤坏死因子α(TNFα)和脂多糖结合蛋白(LBP)水平。测定肝脏TNFα、LBP、诱导型一氧化氮合酶(iNOS)和小窝蛋白-1(一种主要的eNOS抑制剂)的表达以及蛋白激酶B(Akt;一种主要的eNOS激活剂)和eNOS的活性。测量门静脉压力。肝硬化大鼠的血浆HDL水平显著低于对照大鼠。在肝硬化大鼠中,HDL结合的荧光LPS血浆水平比对照大鼠低50%,rHDL给药后恢复。LPS攻击的肝硬化大鼠的血浆TNFα水平显著高于对照大鼠,rHDL给药后显著降低。rHDL给药降低了肝脏TNFα、LBP、iNOS和小窝蛋白-1的表达,恢复了肝脏eNOS和Akt活性,并显著降低了门静脉压力和肝内血管阻力。

结论

在肝硬化大鼠中,rHDL给药可降低LPS诱导的肝脏促炎信号,恢复肝脏eNOS活性,并降低门静脉压力。这表明肝硬化患者循环HDL的减少在过度的促炎反应和肝内eNOS下调中起作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验